Data Favor Twice-Daily vs Once-Daily Chemoradiotherapy in LS-SCLC

Commentary
Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.

In a conversation with CancerNetwork® during the 2025 American Society of Radiation Oncology (ASTRO) Annual Meeting, Bin Gui, MD, spoke about the rationale of a study comparing twice-daily chemoradiotherapy (CRT) with once-daily treatment among patients with limited-stage small cell lung cancer (LS-SCLC). Gui and colleague presented findings from this research in a poster session at the meeting.1

According to Gui, resident physician in the Department of Radiation Medicine at Northwell Health Cancer Institute, prior research demonstrated superior outcomes with twice-daily CRT compared with once-daily therapy, although he noted the limited clinical adoption of the twice-daily schedule based on concerns regarding esophagitis and other logistical challenges. Moreover, he highlighted how findings from the phase 3 ADRIATIC trial (NCT03703297) exhibited the benefit of supplementing CRT with consolidation immunotherapy, inspiring the need to further research how immunotherapy can be combined with radiation in this patient population.2

Findings from the poster presented at ASTRO 2025 showed that twice-daily CRT prolonged 2-year overall survival (OS) by 13% (RR, 1.13; 95% CI, 1.06-1.21) and produced similar progression-free survival (PFS; RR, 1.08; 95% CI, 0.90-1.30) vs once-daily CRT. Data supported the conclusion that the addition of immunotherapy appeared to favor twice-daily CRT vs once-daily CRT based on improved survival and fewer hematologic toxicities.

Transcript:

The assessment of twice-daily vs. once-daily thoracic radiotherapy for LS-SCLC stemmed from a need to determine the optimal radiotherapy regimen as the standard of care with concurrent chemoradiotherapy [CCRT] continues to evolve. Earlier studies suggested twice-daily accelerated radiotherapy improved outcomes. However, its clinical adoption has been limited, particularly in North America, due to concerns about esophagitis and logistical challenges. More recently, the ADRIATIC trial [NCT03703297] demonstrated a significant benefit from adding consolidation immunotherapy following CCRT, creating the need to understand how best to integrate this strategy with the CCRT regimen, including the choice of radiotherapy fractionation schedule.

The addition of immunotherapy appears to favor twice-daily over once-daily CCRT for LS-SCLC, with improved survival and reduced lymphocyte depletion.

References

  1. Gui B, Akerman M, Sekari J, Plann-Curley B, Parashar B. Should we return to old school in a new era? A meta-analysis of twice daily vs. once daily concurrent chemoradiotherapy for limited-stage small cell lung cancer. Presented at the 2025 American Society of Radiation Oncology (ASTRO) Annual Meeting; September 27 – October 1, 2025; San Francisco, CA.
  2. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313-1327. doi:10.1056/NEJMoa2404873
Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Related Content
Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Tim Cortese
October 31st 2025
Article

Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Caroline Seymour
October 26th 2025
Article

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

Russ Conroy
October 25th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.